• Something wrong with this record ?

In vitro activity of ceftazidime-avibactam and comparators against Enterobacterales and Pseudomonas aeruginosa isolates from Central Europe and Israel, 2014-2017 and 2018

K. Kristóf, V. Adámková, A. Adler, E. Gospodarek-Komkowska, A. Rafila, S. Billová, B. Możejko-Pastewka, F. Kiss

. 2021 ; 101 (1) : 115420. [pub] 20210507

Language English Country United States

Document type Journal Article

Persistent link   https://www.medvik.cz/link/bmc22003798

Between 2014 and 2017, 6,662 Enterobacterales and 1,953 P. aeruginosa isolates were collected by 19 centers in four central European countries and Israel. A further 2,585 Enterobacterales and 707 P. aeruginosa isolates were collected in 2018 by 28 centers in seven European countries and Israel as part of the Antimicrobial Testing Leadership and Surveillance (ATLAS) study. A central laboratory performed antimicrobial susceptibility testing using broth microdilution panels according to Clinical Laboratory Standards Institute (CLSI) guidelines. Susceptibility rates among Enterobacterales were highest to ceftazidime-avibactam (≥98.5%), colistin (≥97.3%), and meropenem (≥95.8%). Ceftazidime-resistant and multidrug-resistant (MDR) Enterobacterales subsets were highly susceptible to ceftazidime-avibactam (≥94.9%) and colistin (≥94.7%). Susceptibility rates to colistin among all P. aeruginosa were ≥97.4% and were ≥96.3% among ceftazidime-resistant and MDR subsets. Susceptibility rates to ceftazidime-avibactam were 91.9% (2014-2017), 86.3% (2018) and, in common with comparator agents, were lower among ceftazidime-resistant (≥51.7%) and MDR isolates (≥57.1%).

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc22003798
003      
CZ-PrNML
005      
20220127145843.0
007      
ta
008      
220113s2021 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.diagmicrobio.2021.115420 $2 doi
035    __
$a (PubMed)34091111
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Kristóf, Katalin $u Institute of Laboratory Medicine, Clinical Microbiology Laboratory, Semmelweis University, Budapest, Hungary
245    10
$a In vitro activity of ceftazidime-avibactam and comparators against Enterobacterales and Pseudomonas aeruginosa isolates from Central Europe and Israel, 2014-2017 and 2018 / $c K. Kristóf, V. Adámková, A. Adler, E. Gospodarek-Komkowska, A. Rafila, S. Billová, B. Możejko-Pastewka, F. Kiss
520    9_
$a Between 2014 and 2017, 6,662 Enterobacterales and 1,953 P. aeruginosa isolates were collected by 19 centers in four central European countries and Israel. A further 2,585 Enterobacterales and 707 P. aeruginosa isolates were collected in 2018 by 28 centers in seven European countries and Israel as part of the Antimicrobial Testing Leadership and Surveillance (ATLAS) study. A central laboratory performed antimicrobial susceptibility testing using broth microdilution panels according to Clinical Laboratory Standards Institute (CLSI) guidelines. Susceptibility rates among Enterobacterales were highest to ceftazidime-avibactam (≥98.5%), colistin (≥97.3%), and meropenem (≥95.8%). Ceftazidime-resistant and multidrug-resistant (MDR) Enterobacterales subsets were highly susceptible to ceftazidime-avibactam (≥94.9%) and colistin (≥94.7%). Susceptibility rates to colistin among all P. aeruginosa were ≥97.4% and were ≥96.3% among ceftazidime-resistant and MDR subsets. Susceptibility rates to ceftazidime-avibactam were 91.9% (2014-2017), 86.3% (2018) and, in common with comparator agents, were lower among ceftazidime-resistant (≥51.7%) and MDR isolates (≥57.1%).
650    _2
$a antibakteriální látky $x farmakologie $7 D000900
650    _2
$a azabicyklické sloučeniny $x farmakologie $7 D053961
650    _2
$a ceftazidim $x farmakologie $7 D002442
650    _2
$a fixní kombinace léků $7 D004338
650    _2
$a bakteriální léková rezistence $x účinky léků $7 D024881
650    _2
$a Enterobacteriaceae $x účinky léků $x izolace a purifikace $7 D004755
650    _2
$a enterobakteriální infekce $x mikrobiologie $7 D004756
650    _2
$a lidé $7 D006801
650    _2
$a mikrobiální testy citlivosti $7 D008826
650    _2
$a pseudomonádové infekce $x mikrobiologie $7 D011552
650    _2
$a Pseudomonas aeruginosa $x účinky léků $x izolace a purifikace $7 D011550
650    _2
$a inhibitory beta-laktamasy $x farmakologie $7 D065093
651    _2
$a Evropa $7 D005060
651    _2
$a Izrael $7 D007557
655    _2
$a časopisecké články $7 D016428
700    1_
$a Adámková, Václava $u Institute of Medical Biochemistry and Laboratory Diagnostics, General University Hospital, Prague, Czech Republic
700    1_
$a Adler, Amos $u Clinical Microbiology Laboratory, Tel Aviv Sourasky Medical Centre, Tel Aviv, Israel
700    1_
$a Gospodarek-Komkowska, Eugenia $u Department of Microbiology, Nicolaus Copernicus University in Toruń, Ludwik Rydygier Collegium Medicum in Bydgoszcz, Poland
700    1_
$a Rafila, Alexandru $u National Institute of Infectious Diseases 'Matei Bals', Bucharest, Romania
700    1_
$a Billová, Sabina $u Pfizer, spol. s r.o., Prague, Czech Republic
700    1_
$a Możejko-Pastewka, Barbara $u Pfizer Polska Sp. z o.o., Warsaw, Poland
700    1_
$a Kiss, Ferenc $u Pfizer Kft., Budapest, Hungary. Electronic address: Ferenc.Kiss@pfizer.com
773    0_
$w MED00001396 $t Diagnostic microbiology and infectious disease $x 1879-0070 $g Roč. 101, č. 1 (2021), s. 115420
856    41
$u https://pubmed.ncbi.nlm.nih.gov/34091111 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20220113 $b ABA008
991    __
$a 20220127145840 $b ABA008
999    __
$a ok $b bmc $g 1751303 $s 1154947
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2021 $b 101 $c 1 $d 115420 $e 20210507 $i 1879-0070 $m Diagnostic microbiology and infectious disease $n Diagn Microbiol Infect Dis $x MED00001396
LZP    __
$a Pubmed-20220113

Find record

Citation metrics

Archiving options